Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEEOX Neoadjuvant Chemotherapy for Borrmann Type 4 Gastric Cancer
NCT02949258Phase 2Unknown
- Sponsor
- Jinling Hospital
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, etoposide, epirubicin and tegafur in linitis plastica (LP), sponsored by Jinling Hospital. Primary endpoint: 2-year survival rate. Status: unknown.
02
Drugs
oxaliplatinetoposideepirubicintegafur
03
Conditions
linitis plastica (LP)
Beyond the preview
Go deeper on NCT02949258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949258.